All In Biotech

Drug Trial Radar · NCT07694557

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

A Phase 1, Randomized, Double-Blind, Ascending-Dose Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Respiratory Syncytial Virus mRNA Vaccine YKYY025 Injection in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Jul 29, 2026

Primary completion

Jul 1, 2028

Study completion Oct 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • YKYY025 groupDrug

    intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 for injection

  • YKYY025 Placebo groupDrug

    intramuscular, a single intramuscular injection of the corresponding dose of YKYY025 Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events(AEs)Time frame: within 30 days after vaccination
  2. Serious adverse events (SAEs)Time frame: within 12 months after vaccination
  3. Heart rate in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
  4. PR interval in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
  5. RS duration in 12-lead electrocardiogram (ECG)Time frame: within 4 days after vaccination
  6. QT/QTC in 12-lead electrocardiogramTime frame: within 4 days after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Anning First People's Hospital

    Anning, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.